Navigation Links
Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema

to leave their jobs and one patient in five takes prolonged sick leave resulting in high socio-economic and individual patient burden.

About Alitretinoin Alitretinoin is an investigational drug being developed in Phase III clinical trials by Basilea as a novel treatment for severe refractory Chronic Hand Eczema (CHE), a complex disease for which no effective treatment options are currently available. Alitretinoin has been shown to be effective in Phase II and Phase III clinical studies in patients with severe refractory CHE.

In a phase II double-blind international multi-center placebo controlled trial of 319 patients with moderate and severe chronic hand eczema refractory to topical treatment, alitretinoin was clinically effective in 29% to 53 % of patients depending on the dose administered. Alitretinoin was generally well tolerated with dose dependent headache observed as the most common side effect.

Basilea's first pivotal phase III international multi-center placebo-controlled BACH trial (Benefit of Alitretinoin in Chronic Hand eczema) showed that alitretinoin was effective in patients suffering from severe refractory CHE, as determined by the endpoint of clear and almost clear hands.

This randomized double-blind phase III pivotal study was the largest therapeutic trial ever performed in chronic hand eczema with 1,032 patients whose severe chronic disease was unresponsive to topical steroids. The patients were randomized either to a once-daily dose of 30mg or 10mg of alitretinoin, or placebo for a treatment duration of up to 24 weeks. Alitretinoin's efficacy was significantly superior to placebo in both the high and the low dose regimen. In the 30mg group 48% of patients and in the 10 mg group 28% of patients reached the primary endpoint. In this study alitretinoin was again generally well tolerated with dose dependent headache and blood lipid elevations as the most commonly observed side effects.

Alitretinoin is a teratogen
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
2. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:12/15/2009)... Bend Research Inc. announced,today that its clients ... an,excipient used in technologies developed by the firm to ... Bend Research clients may now reference ... regulatory filings with the FDA, Bend Research officials said. ... new development and know it will assist our,clients in ...
(Date:12/14/2009)... Dec. 14 BioTrends Research Group, Inc. ... a syndicated publication offering comprehensive insight into the ... based on a comparison of self-reported treatment approaches ... level data for over 1,000 RA patients who ... To be eligible for the audit, patients had ...
(Date:12/14/2009)... 14 Seven leading cancer ... US Oncology Research participated in ... the 2009 San Antonio Breast ... at the Henry B. Gonzalez ... Texas . Fifteen others presented ...
Breaking Medicine Technology:Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient 2New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 2New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Acupuncture may bring relief for a common condition in women 54970 1Acupuncture may bring relief for a common condition in women 54970 2Switching on the power of stem cells 9639 1Switching on the power of stem cells 9639 2Princeton team learns why some drugs pack such a punch 9635 1Princeton team learns why some drugs pack such a punch 9635 2Princeton team learns why some drugs pack such a punch 9635 3
... Strativa,Pharmaceuticals, the proprietary products division of ... today announced that its development partner,Alfacell Corporation ... preliminary,statistical analysis of data from its confirmatory ... ONCONASE (ranpirnase), did not meet statistical,significance for ...
... Showed Clinically Meaningful Benefits for Patients with,Chemotherapy-Induced ... May 29 ,GlaxoSmithKline (GSK) today announced the ... U.S. Food and Drug Administration and new ... (casopitant), a novel,investigational NK-1 receptor antagonist. The ...
Other Medicine Technology:Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial 2Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial 3Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial 4GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 2GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 3GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 4GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 5GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 6GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 7GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 8
(Date:12/15/2009)... CHICAGO, Dec. 15 Research shows a ... return on investment as building a culture of ... improved performance(1). According to a new white paper ... wellness solutions, the workplace represents an ideal setting ... and building and sustaining a corporate culture of ...
(Date:12/15/2009)... CHICAGO, Dec. 15 The following is being ... ,, Remarks by: Vera Rulon, MS, RHIT, CCS, ... morning, everyone and thank you joining us... ,, On ... great pleasure to introduce our next chief executive officer, ... embarked on a nationwide search for someone who we ...
(Date:12/15/2009)... midwife are generally associated with different tests and/or ... more. Women, doctors and midwives are agreed that ... sexual health, reveals a thesis from the Sahlgrenska ... Many young women see sex as a problem, ... answered questions about their sex lives, their relationships ...
(Date:12/15/2009)... Spanish scientists have found the first potential immunological clue ... by the pandemic H1N1 virus. , The study ... patients, 15 outpatients and 15 control subjects in 10 ... and August 2009. Researchers from the Hospital Clinico Universitario ... found high levels of a molecule called interleukin 17 ...
(Date:12/15/2009)... people really benefit from their looks, and in what ... Georgia and the University of Kansas found that yes; ... and therefore an increased sense of psychological well-being. This ... spend billions of dollars each year trying to become ... issue of Personal Relationships , also determines that ...
Breaking Medicine News(10 mins):Health News:Optimizing Corporate Culture is Critical to the Success of Wellness Programs 2Health News:Dowling Press Availability Tuesday, December 15, 2009 / 10:00 a.m. CST 2Health News:More about sex and relationships needed at gynecological visits 2Health News:First immunological clue to why some H1N1 patients get very ill or die 2Health News:The importance of attractiveness depends on where you live 2
... Inc. (NYSE: ARE ) today announced the Company ... Monday, February 9, 2009, at 3:00 p.m. Eastern Time (ET), ... results for the fourth quarter and year ended December 31, ... before the market opens on Monday, February 9, 2009. , ...
... 2 Walden University,s M.S. in ... Council for Accreditation,of Counseling and Related Educational Programs ... for Higher Education,Accreditation that accredits counselor preparation master,s ... education institution that offers a,CACREP-accredited M.S. degree in ...
... the formation of fibroblasts during development also promotes their ... et al. in the February 9, 2009 issue of ... conversion of epithelial cells into fibroblast-like mesenchymal cells is ... The transcription factor Snail1 induces this conversion (known as ...
... Pharmacy Retail Level, Kidz-Med Thermofocus 5-in-1 Debuts on "Fox ... Resources (Pink Sheets: ASFX) today announced that pharmacy retail ... of 2008 compared to the 4th quarter of 2007. ... the economic recession, since implementing particular offline and online ...
... Availity, LLC, a leading health,information network, today ... of medical and behavioral health management software, ... transactions. Health care,providers with MedEZ software can ... Information Network. The partnership provides MedEZ,customers with ...
... @Heart Campaign Encourages the 44 Million Women Living with or ... Heart Health -WASHINGTON, Feb. 2 Heart disease is the ... still not receiving the same in-hospital treatment that men do ... more likely to die.(ii) In an effort to address ...
Other Medicine News:Health News:Walden University's M.S. in Mental Health Counseling Program Receives CACREP Accreditation 2Health News:Walden University's M.S. in Mental Health Counseling Program Receives CACREP Accreditation 3Health News:Fibroblasts invade at a snail's pace 2Health News:Q4 2008 Sales Increase for Health and Safety Products Company 2Health News:Q4 2008 Sales Increase for Health and Safety Products Company 3Health News:Availity Partners With MedEZ 2Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 2Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 3Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 4Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 5
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... either EDTA K2 or EDTA K3 ... and therefore blocks the coagulation cascade. ... EDTA anticoagulated blood sample are stable ... tubes are for the examination of ...
Glass Whole Blood Tube with K3EDTA...
Medicine Products: